Further, these data implied that PUS7 is important for the NMS-E973-induced repression of CRC metastasis in vivo and in vitro and that HSP90 inhibitors combined with PUS7 suppression exhibit an activity superior to that of monotherapy targeting HSP90. This evidence concerns the gene HSP90AB1 and colorectal carcinoma.